Nothing Special   »   [go: up one dir, main page]

WO1989006689A1 - Constructions genetiques renfermant le gene amyloide cerebral d'alzheimer - Google Patents

Constructions genetiques renfermant le gene amyloide cerebral d'alzheimer Download PDF

Info

Publication number
WO1989006689A1
WO1989006689A1 PCT/US1989/000130 US8900130W WO8906689A1 WO 1989006689 A1 WO1989006689 A1 WO 1989006689A1 US 8900130 W US8900130 W US 8900130W WO 8906689 A1 WO8906689 A1 WO 8906689A1
Authority
WO
WIPO (PCT)
Prior art keywords
amyloid
cdna
cells
gene
dna
Prior art date
Application number
PCT/US1989/000130
Other languages
English (en)
Inventor
Charles A. Marotta
Sayeeda Zain
Original Assignee
The Mclean Hospital Corporation
University Of Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Mclean Hospital Corporation, University Of Rochester filed Critical The Mclean Hospital Corporation
Publication of WO1989006689A1 publication Critical patent/WO1989006689A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease

Definitions

  • the present invention was made using funds of the United States government.
  • the U.S. government is granted a royalty-free, nonexclusive, worldwide and paid-up license to this invention.
  • the present invention relates to recombinant DNA technology and to products and processes involved in the cloning preparation, expression, and use of genes for amyloid derived from the brain of Alzheimer's Disease patients.
  • Senile plaques found in abundance in the Alzheimer's Disease (AD) brain represent a hallmark feature of this disorder and have been correlated with the degree of intellectual impairment (2, 3).
  • the plagues are composed of extracellular amyloid, reactive cells, and degenerating neurites (1).
  • the proteinaceous amyloid is also associated with the cerebral vasculature of the AD brain (6).
  • Amyloid is composed of fibrils of 4-8 nm diameter that form the core of the plaques (4).
  • the ⁇ -polypeptide derived from purified ⁇ - amyloid, is disclosed in Glenner et al .. U.S. Patent No. 4,666,829, filed May 15, 1985. This patent also discloses antibodies made to the first 10 amino acids of the ⁇ -polypeptide.
  • amyloid gene product merits intense scrutiny since it is a major neuropathologic manifestation of AD. At present, no direct information is available on mechanisms that regulate amyloid metabolism and which are responsible for the increased deposition of amyloid in the AD brain.
  • the gene has been localized to chromosome 21, as has the gene for familial AD (10, 11). Therefore, complex interactions involving chromo some 21 gene products (31), the processing of transcripts or of the protein precursor, an unusual precursor structure, and/or interaction with the environment may contribute to the unusually high content of amyloid in the AD brain (30).
  • the genetic transcript for amyloid that is expressed specifically in the AD brain is the same as in non-demented cases.
  • nucleotide sequence variations occurring at certain sites may affect mRNA activity or stability; or, more than one form of amyloid protein may be synthesized.
  • the predominant type of amyloid mRNA derived from the AD brain is the same as from non-Alzheimer sources, then in order to explain the overabundance of amyloid typically present in the AD brain, attention would have to be focused upon elucidating the fine details of genetic control mechanisms affecting transcription levels or the regulation of amyloid protein turnover at the cellular level.
  • cDNA libraries from AD brain mRNA were prepared and the amyloid precursor cDNA identified. Coding and 3'-non-coding regions of cDNA sequences that surround and include the known A4-amyloid polypeptide structure are disclosed. The cloned amyloid insert is also used to compare AD and control mRNAs on Northern blots and the results are contrasted with those obtained with a glialspecific mRNA.
  • the invention is also drawn to recombinant molecules containing the AD-amyloid gene, such as plasmids; to hosts transformed therewith; to methods of production of AD-amyloid; to diagnosis of AD; and to genetic models for AD, such as transfected cell lines and transgenic mice.
  • the transfected cells and transgenic mice of the invention are designed to produce a cellular model for the overproduction of amyloid.
  • the cells which include neuronal, glial and other types, can be characterized with anti-amyloid monoclonal antibodies (mabs) as described in copending U.S. Patent Application 105,751, filed 10/8/87, incorporated by reference herein in its entirety.
  • Other characterization methods include in situ hybridization, molecular and cellular procedures, and light and electron microscopic methods.
  • transfected cells and transgenic mice of the invention are useful for determining the extent to which the A4 or other amyloid precursor domains accumulate, and possibly precipitate, either intracellularly or extracellularly.
  • the transfected cell lines may be extensively examined at the levels of transcription, translation and RNA metabolism.
  • the cells may be subjected to biological agents that affect the intracellular turnover of amyloid.
  • the extent to which transfected cells resemble or differ from amyloid producing cells of the AD brain may be assessed. This may be done by assessing amyloid production in the AD brain by immunologic and in situ hybridization methods (30, 34, 49).
  • the mouse model provides a new and invaluable medium with which to explore the molecular pathogenesis of amyloidosis relevant to AD and to serve as an animal assay system to screen potentially therapeutic agents.
  • the latter include drugs that prevent or limit the overproduction of amyloid in the mammalian brain, or which increase the degradation of amyloid.
  • the preparation of cell or animal models that overexpress the amyloid precursor are intended as experimental tools to gain insight into the synthesis and metabolism of amyloid that may have relevance to the overaccumulation of amyloid in the AD brain. These models do not depend for their significance on whether or not the amyloid gene is or is not duplicated in AD.
  • the transfected cells and transgenetic mice of the invention are not intended to test various hypotheses, but rather, to serve as biological models that allows evaluation and modifications of amyloid overproduction in defined cells and neural tissues.
  • transfected cells and transgenic mice By means of transfected cells and transgenic mice, a means to determine whether or not overproduction of amyloid intracellularly is sufficient to cause deposition at intracellular or extracellular sites is provided. In addition, a means to determine the consequences of this process for normal cellular metabolism is also provided.
  • Fi ⁇ ure 1 shows the Eco RI digestion products of lambda gt 11 cDNAs containing A4-amyloid inserts that corresponded to fetal A4-amyloid (9). The bands were resolved on a 1.2% agarose-ethidium bromide gel. Lanes A-E are representative of most inserts obtained; lane F contains the amy37 insert which yielded large and small fragments of the indicated kb sizes.
  • Figure 2 shows the sequence analysis strategy for the amy37 insert.
  • the fragment of 1564 base pairs were digested with Eco RI and Rsa I and the resulting subfragments were analyzed as described in the Materials and Methods.
  • Figure 3 shows the sequence of amy37 cDNA. Shown is the nucleotide structure with the corresponding amino acids. The nucleotide positions are indicated at the right and the amino acid positions are shown in parentheses at the left; the numbering scheme was suggested in reference 9.
  • the A4 amyloid protein sequence (9) is underlined. An asterisk indicates the termination codon and is followed by the 3'-non-coding sequence.
  • Figure 4 shows Northern blots of control and AD mRNAs identified with the amy37 probe. Twice purified poly (A+) RNA wa ⁇ subjected to electrophoresis on a formaldehyde-agarose gel and hybridized with the nick-translated amy37 probe.
  • Lane A contains size markers (in kb). Lanes B-H contain poly(A+) RNA from the following cases identified in terms of diagnosis (A for Alzheimer and C for control), age and postmortem interval: (B) A77, 10hr; (C) C73, 13 hr; (D) A67, 2.5 hr; (E) C57, 13 hr.; (F) A65, 3.75 hr; (G) C73X, 10.5 hr; (H) C91, 18 hr.
  • Figure 5 shows an endonuclease restriction map of brain amyloid cDNA.
  • Figure 6 shows the construction and screening of an AD amyloid-specific cDNA library from alzheimer brain A77 mRNA to isolate the 5' end of mRNA.
  • the unique Eco RI sites in Min (2A) and Moh (2B) vectors are used to insert the Eco RI fragments of the A4 ( ⁇ -amyioid) cDNA from the A4 peptide coding domain, the precursor domain, and the c-terminal end domain.
  • the unique Eco RI site is converted to a Sac II site; the resulting vehicle is used to clone the complete cDNA with heterologous SV40 (Mas vectors, 2A) or JC (Ameer vectors, 2B) viral control regions.
  • the Mas vectors are used for the same purpose. All the described vectors are used to prepare transfected cells and transgenic mice.
  • Figure 8 depicts a comparison of the DNA sequences of the indicated vectors from the unique Hind III site beyond the unique cloning site (C.S.) indicated by black triangles.
  • the authentic SV40 coded amino acids are written in small letters starting with the initiation methionine of the SV40 T/t antigens; amino acids written in capital letters represent amino acids coded by the synthetic Eco RI linker followed by vector sequences.
  • An open triangle locates a 6 bp deletion in Min 2.
  • the lower panel of Fig. 8 shows the sequences of the Sac II site that was introduced into Min vectors to produce the Mas vectors 1, 2 and 3. The cloning sites and base pair deletion site are indicated.
  • Figure 9 The indicated cells were transfected with the Min 2 vector, which was linked to the 1.1 kb amy 37 insert containing the A4 region, and were cotransfected with pKOneo (for Genaticin resistance) and pSV 2 CAT (for the transfection assay). The cells shown survived in the G418 media indicating successful transfection.
  • TOP panel PC12 cells.
  • Middle Panel C6 cells.
  • Lower Panel Cos A2 cells.
  • Gene A DNA sequence which encodes through its template or messenger RNA a sequence of amino acids characteristic of a specific peptide.
  • cDNA includes genes from which the intervening sequences have been removed.
  • recombinant DNA is meant a molecule that has been recombined by in vitro splicing cDNA or genomic DNA sequence.
  • Cloning Vehicle A plasmid or phage DNA or other DNA sequence which is able to replicate in a host cell.
  • the cloning vehicle is characterized by one or a small number of endonuclease recognition sites at which such DNA sequences may be cut in a determinable fashion without loss of an essential biological function of the DNA, which may contain a marker suitable for use in the identification of transformed cells. Markers, for example, are tetracycline resistance or ampiciliin resistance.
  • the word "vector” is sometimes used for cloning vehicle.
  • Expression Vehicle A vehicle similar to a cloning vehicle but which is capable of expressing a given structural gene in a host, normally under control of certain control sequences.
  • Expression Control Secruence A sequence of nucleotides that controls or regulates expression of structural genes when operably linked to those genes. They include the lac systems, the trp system, major operator and promoter regions of phage lambda, the control region of fd coat protein and other sequences known to control the expression of genes in prokaryotic or eukaryotic cells.
  • Promoter A DNA sequence in which RNA polymerase binds and initiates transcription of an adjacent gene(s).
  • host is meant to include not only prokaryotes, but also such eukaryotes as yeasts, filamentous fungi, as well as plant and animal cells.
  • Prokaryote is meant to include all organisms without a true nucleus, including bacteria.
  • AD-Amyloid This term is meant to include polypeptides which are derived from the amyloid of AD brain.
  • A4-Amyloid This term is meant to include an A4-amyloid polypeptide from any species, especially from AD human brain (8, 9).
  • the term is also used in this invention to include any analogue, homologue, mutant or derivative of a naturally occurring A4-amyloid.
  • the term is also meant to include fragments having less than the naturally occurring number of amino acids, such as partial fragments of natural A4-amyloid which retain the biological or immunological characteristics of the polypeptide specifically disclosed in this application.
  • the term is also used to include any product which comprises the sequence of a naturally occurring A4-amyloid or analogue thereof, together with one or more flanking amino acids, which still have the same immunologic characteristics.
  • the invention comprises the genetic sequences encoding AD-amyloid, vehicles containing the genetic sequence, hosts transformed therewith, AD-amyloid production by transformed host expression, and utilization of AD-amyloid in diagnosis or in therapeutic utilizations.
  • the DNA sequence coding for AD-amyloid may be derived from a variety of sources, but, in this invention, most particularly from AD brain tissues. Postmortem RNA isolation procedures can be followed (12). For example, mRNA encoded for AD-amyloid may be isolated. The mRNA may then be converted to cDNA by techniques known to those skilled in the art. Probes may be synthesized based on the known amino acid sequence of A4-amyloid peptide.
  • An AD DNA sequence encoding A4-amyloid may be recombined with vector DNA in accordance with conventional techniques, including blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide appropriate termini, filling in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and ligation with appropriate ligases.
  • Eukaryotic hosts may be mammalian cells capable of culture in vitro, particularly leukocytes, more particularly myeloma cells or other transformed or oncogenic lymphocytes, e.g., EBV-transformed cells.
  • non-mammalian cells may be employed, such as bacteria, fungi, e.g., yeast, filamentous fungi, or the like.
  • Possible hosts for AD-amyloid production are mammalian cells, grown in vitro in tissue culture or in vivo in animals. Mammalian cells may provide post-translational modifications to AD-amyloid molecules including correct folding or glycosylation of the correct sites. Mammalian cells which may be useful as hosts include cells of fibroblast origin such as VERO or CHO-K1, or cells of lymphoid origin, such as the hybridoma SP2/P-AG14 or the myeloma P3x63Sgh, and their derivatives. Usually the AD-amyloid construct will be part of a vector having a replication system recognized by the host cell.
  • a prokaryotic cell is transformed by a plasmid carrying the AD-amyloid encoded gene.
  • Bacterial hosts of particular interest include E. coli K12 strain 294 (ATCC 31446), E. coli X1776 (ATCC 31537), E. coli W3110 (F-, lambda-, prototropic (ATCC 27325)), and other enterobacteriaceaes such as Salmonella tvphimurium or Serratia marcescens. and various Pseudomona species. Under such conditions, the AD-amyloid will not be glycosylated.
  • the prokaryotic host must be compatible with the replicon and control sequences in the expression plasmid.
  • such vectors containing replicon and control sequences which are derived from species compatible with a host cell are used in connection with the host.
  • the vector ordinarily carries a replicon site, as well- as specific genes which are capable of providing phenotypic selection in transformed cells.
  • the expression of the AD-amyloid encoded DNA can also be placed under control of other regulatory sequences which may be homologous to the organism in its untransformed state.
  • lactose-dependent E. coli chromosomal DNA comprises a lactose or lac operon which mediates lactose utilization by elaborating the enzyme ⁇ -galactosidase.
  • the lac control elements may be obtained from bacteriophage lambda plac5, which is infective for E. coli.
  • the lac promoter-operator system can be induced by IPTG.
  • promoter/operator systems or portions thereof can be employed as well.
  • colicin E1 galactose, alkaline phosphatase, tryptophan, xylose, tax, and the like can be used.
  • vectors For a mammalian host, several possible vector systems are available for expression.
  • One class of vectors utilize DNA elements which provide autonomously replicating extra-chromosomal plasmids, derived from animal viruses such as bovine papilloma virus, polyoma virus, adenovirus, or SV40 virus.
  • a second class of vectors relies upon the integration of the desired gene sequences into the host chromosome.
  • Cells which have stably integrated the introduced DNA into their chromosomes may be selected by also introducing one or markers which allow selection of host cells which contain the expression vector.
  • the marker may provide for prototropy to an auxotrophic host, biocide resistance, e.g., antibiotics, or heavy metals, such as copper or the like.
  • the selectable marker gene can either be directly linked to the DNA sequences to be expressed, or introduced into the same cell by co-transformation. Additional elements may also be needed for optimal synthesis of mRNA. These elements may include splice signals, as well as transcription promoters, enhancers, and termination signals.
  • the cDNA expression vectors incorporating such elements include those described by Okayama, H., Mol. Cel. Biol. 2:280 (1983), and others.
  • transcriptional and translational regulatory sequences may be employed, depending on the nature of the host.
  • the transcriptional and translational signals may be derived from viral sources, such as adenovirus, bovine papilloma virus, simian virus, or the like, where the regulatory signals are associated with a particular gene which has a high level of expression.
  • promoters from mammalian expression products such as actin, collagen, myosin, etc., may be employed.
  • Transcriptional initiation signals may also be selected which allow for repression or activation, so that expression of the genes may be modulated.
  • regulatory signals which are temperature-sensitive so that by varying the temperature, expression can be repressed or initiated, or are subject to chemical regulation, e.g., metabolite.
  • the DNA constructs may be introduced to an appropriate host.
  • Various techniques may be employed, such as protoplast fusion, calcium phosphate precipitation, electroporation or other conventional techniques.
  • the cells are grown in media and screened for appropriate activities. Expression of the gene(s) results in production of the AD-amyloid.
  • the host cells for AD-amyloid production may also be immortalized cells, primarily myeloma or lymphoma cells. These cells may be grown in an appropriate nutrient medium in culture flasks or injected into a synergistic host, e.g., mouse or rat, or immunodeficient host or host site, e.g., nude mouse or hamster pouch.
  • a synergistic host e.g., mouse or rat
  • immunodeficient host or host site e.g., nude mouse or hamster pouch.
  • the AD-amyloid of the invention may be isolated and purified in accordance with conventional conditions, such as extraction, precipita- tion, chromatography, affinity chromatography, electrophoresis, or the like.
  • AD- amyloid One application of the cDNA coding for AD- amyloid is for the diagnosis of Alzheimer's disease.
  • the defect causing familial AD is unlikely to be located in or near the amyloid gene (31, 32).
  • Tanzi et al. (31) have suggested that the disorder is either caused by altered expression of a second independent gene on chromosome 21, that may be overexpressed along with the amyloid gene, or by a long range effect of the defect on the expression of the amyloid gene.
  • the latter could arise from a structural abnormality on chromosome 21 causing overexpression of the amyloid gene either by promoting mitotic nondisjunction leading to somatic cells trisomic for this autosome, or by duplication of a large region of the chromosome containing the amyloid gene.
  • AD Alzheimer's disease
  • the mutation underlying AD may directly alter the expression of the amyloid gene due to a distant cis-acting element (31).
  • overexpression of the amyloid gene may, in some cases, be detectable.
  • the amyloid gene of the invention or portions thereof can be labeled and used as probes to develop a test and kit for diagnostic screening.
  • cell lines that express the amyloid gene Another application is the development of cell lines that express the amyloid gene.
  • the value of such cell lines is that they can be used to screen drugs that are potentially useful for treating Alzheimer's disease by stopping the production of amyloid. The latter is assayed by the use of monoclonal antibodies.
  • the single most serious obstacle to developing suitable anti-Alzheimer drugs has been the lack of a suitable biological assay system. The establishment of the cell lines will provide one remedy for the problem.
  • transfected cells and transgenic mice carrying an overabundance of the amyloid gene may ultimately serve as the most useful models for the increased deposition of amyloid in the AD brain.
  • cDNA mRNA-encoding portion of the gene
  • Cloned genes that have been introduced into the mouse germ line show appropriate tissue-specific and stage specific patterns of expression (53), despite their integration into apparently random sites in the host genome. Indeed, there is precedent for using the transgenic mouse model to introduce new genes into the mammalian brain and to obtain expression of the genetic product (59).
  • the cells and mice may be the ideal vehicles for evaluating drugs that prevent, or limit the production of amyloid or which increase the degradation of amyloid in vivo.
  • the described inventions may be exemplary with regard to elucidating previously unknown aspects of the molecular pathogenesis of AD.
  • AD case I was a 67-year-old male (referred to as A67) with a three-to-four-year history of progressive dementia.
  • the clinical diagnosis of Alzheimer's disease was made after neurological, psychiatric, and neuropsychological evaluations.
  • the neuropathological examination was made after a postmortem interval of 2.5 hours and revealed abundant senile plaques and moderate numbers of neurofibrillary tangles in the neocortex with similar changes in the hippocampus and amygdala.
  • Case II was a 77-year-old male (referred to as A77) with a nine-year history of progressive dementia diagnosed on the same basis as Case I. Abundant neuritic plaques and moderate neurofibrillary tangles were observed throughout the cerebral cortex with similar hippocampal changes. The neuropathological diagnosis was made after a postmortem interval of 4.25 hours. RNA preparations used for Northern blots were obtained from the above source and from the McLean Hospital Brain Tissue Resource Center.
  • RNA was prepared from cortex as described in reference 12 with the following modifications:
  • Two different lambda-gtll recombinant cDNA libraries were prepared separately from A67 and A77 postmortem brain poly(A+) RNAs by the general methods previously described (13, 14). After propagation, the A67 library contained 0.5 ⁇ 10 6 plaques (18% clear) . . Immunologic screening of the library was conducted (14) to identify the ⁇ -galactosidase-AD-amyloid chimera protein using a mixture of monoclonal antibodies (Mabs) made to a synthetic 28-amino-acid polypeptide with the amino acid sequence reported for a plaque amyloid polypeptide referred to as A4 (8). The preparation and characterization of the Mabs are described in copending U.S. Serial No. 105,751, filed October 8, 1987, and herein incorporated by reference in its entirety.
  • amy10 had an insert of approximately 200 nucleotides that was positive with both the antibody and the oligonucleotide probes.
  • the amy10 insert was subcloned into the pGEM plasmid and partial nucleotide sequences were derived (15).
  • the sequenced molecule demonstrated a region that matched predicted codons of the A4 fetal amyloid amino acids and included nucleotides 1794-1878 (9).
  • the insert as well as a synthetic oligonucleotide based upon the amy10 partial sequence data was synthesized and utilized for screening purposes.
  • a second, and more efficient, cDNA library was prepared from A77 poly(A+) RNA.
  • the amplified library contained 5 ⁇ 10 6 plaques (50% clear) with inserts sizes of 0.3-2.5 kb. Forty positive clones were identified, thirty of which had inserts of at least 1.0 kb and two with inserts of 1.5 kb or larger. One of these, amy37., was subjected to further analysis. The clone amy37 has been deposited before the filing date of the present application at the American Type Culture Collec tion, Rockville Maryland, under the terms of the Budapest Treaty and given accession number 40371.
  • Amy37 Recombinant Restriction enzymology of the recombinant phage DNA was carried out using Eco RI restriction endonuciease and inserts were sized by resolving on 1.2% agarose gels.
  • the amy37 insert was further subcloned into PGEM vectors and sequenced directly using the chemical modification method (15).
  • Amy37 yielded two inserts of approximately 1.1 and 0.5 kb in length that were, in addition, subcloned in the Eco RI site of the M13mp8 vector.
  • the 1.1 kb insert was further digested with Rsa I and subcloned into the Hind II site of M13mp8.
  • Singlestranded DNA prepared from the M13 phages (16) was sequenced by the chain termination method (17) using ( 35 S)-dATP and a buffer gradient gel (18). The data were analyzed with a computer program (19).
  • riboprobes (22).
  • the latter were used for hybridization where indicated.
  • the GFAP insert, GSS-11 was labeled (21) and used for hybridization.
  • the DNA was isolated from the recombinant phage particles, digested with Eco RI endonuciease, and resolved on a 1.2% agarose-ethidium bromide gel ( Figure 1).
  • Clone amy37 ( Figure 1, lane f) had a cDNA insert consisting of two Eco RI fragments of approximately 1.1 and 0.5 kb derived from the total insert due to an internal Eco RI site ( Figures 1 and 2).
  • the size of the full-length amyloid precursor cDNA isolated from fresh fetal brain was reported to be 3.2-3.4 kb (9).
  • the postmortem poly(A+) RNA yielded at least one insert that represented approximately half the length of the fetal precursor molecule.
  • the cloned insert was subjected to sequence analysis as described in Materials and Methods and summarized in Figure 2.
  • the derived sequence ( Figure 3) matches exactly the corresponding region of the precursor amyloid cDNA sequence derived from the fetal human brain (9).
  • the region encoded by amy37 begins in the translated region at amino acid 431 (using the numbering scheme suggested in reference (9) and includes the A4 amyloid region, consisting of 42 or 43 amino acids, that is deposited in the AD brain (9) (underlined in Figure 3), and 771 nucleotides of the 3'-non-coding segment.
  • Figure 4 depicts the detailed restriction endonuciease map that includes the amy
  • a special amyloid mRNA-specific cDNA library was prepared using three different primers for the first strand synthesis.
  • Primer one (P1) was a synthetic oligonucleotide that corresponds to nucleotide nos. 1795-1883 of amy 37 from the noncoding strand (see Fig. 3).
  • the other two primers that were used (P2 and P3) were two short restriction endonuciease fragments generated from amy 37 DNA.
  • the two primers were as follows: P1 was a 69 base pair long Haelll-Haelll fragment extending from nucleotides 1438-1509 (Fig: 3); P2 was a 288 base pair long Haelll-EcoRI fragment extending from nucleotides 1507-1795 (Fig. 3). The fragments are indicated schematically in Figure 5.
  • the first strand cDNA synthesis was conducted using A77 AD mRNA that had been twice purified through oligo(dT) cellulose, as the template.
  • One of the primers was used in each of three independent reactions as described earlier.
  • the RNA was treated with methyl mercury hydroxide at a concentration of 8 mM for 10 minutes at room temperature and then diluted to 2 mM final concentration.
  • a special repair synthesis was thus constructed to produce an amyloid specific cDNA library.
  • a lawn of E. coli was transfected with recombinant cDNA molecules at a density of 3000 pfu/150 mm plate and transferred to cellulose nitrate membrane filters as described earlier in this application.
  • Figure 6 depicts the sizes of cDNA synthesized using this approach.
  • the size of the transcript needed to reach the 5' end (or at 'least the AUG initiation codon) at around 1.5 kb.
  • Our cDNA lengths sized on the gels fall into this category. Eleven recombinants were randomly picked which were positive with the short probe after growth on E. coli. The phage DNA was then.- isolated. The DNA was subjected to EcoRI restriction endonuciease analysis to size the inserts and to choose the longest recombinant to finish the repair synthesis and for further characterization by sequence analysis.
  • One of the inserts, amy-x14 had an insert of approximately 1.1 to 1.5 kb (see Fig. 6).
  • amy-x14 clone has been deposited before the filing date of the present application at the American Type Culture Collection, Rockville, Maryland, under the terms of the Budapest Treaty and given accession number 40370.
  • the repair and joining of the two clones amy37 and amy-x14 is conducted to produce a fulllength AD amyloid cDNA clone as soon as the nucleotide sequence of the amy-x14 at the 3' end is completed. If necessary, this molecule will then be joined to another insert that completely covers the 5' end of the amyloid mRNA. If the 3' terminus of amy-x14 harbors the Haelll to EcoRI fragment as a primer, then the unique Sad site (Fig. 5) is utilized to join the long EcoRI-SacI fragment of amy-x14 to the Sacl-Hindlll unique fragment of amy37 cDNA. If the 3' end of amy-xl4 starts at the short Haelll-Haelll fragment, then the BamHI approach, described below, is adapted.
  • the unique BamHI-Hindlll fragment of amy-37 is isolated.
  • the unique BamHI-BamHI amyxl4 fragment is isolated.
  • the two fragments are ligated together at the BamHI site and molecules with head to tail orientation are isolated using the KPN I and Bal I digestion patterns.
  • the molecules with the head to tail orientation are Klenow repaired to destroy the terminal BamHI and Hindlll restriction sites and selected linkers may be added.
  • the cDNA insert is then inserted into vectors for cellular transfection and mouse transgenic experiments.
  • RNA is retained by AD postmortem brains in amounts that are sufficient for functional studies and molecular cloning (12, 24, 25).
  • Northern blot analyses were carried out to compare the AD amyloid mRNA with controls, and then a second mRNA was utilized for further comparisons (see below).
  • the AD cortex contains a doublet at 3.2 and 3.4 kb that is recognized by the amyloid probe.
  • RNA preparations from conventionally obtained AD cases only one was partly degraded with respect to the full-length mRNA; controls had predominantly intact mRNA.
  • the Northern blots indicated that the levels of AD cortical amyloid mRNA were not typically higher than in controls.
  • the AD brain is rich in ribonucleases and a combination of transcriptional and degradative factors have been implicated in lowering RNA levels (13).
  • the presence of partly degraded RNA in some postmortem preparations may be unrelated to the usual metabolic pathway for RNA turnover.
  • the present studies do not support the view that using only a small number of probes is sufficient to assess the overall intactness of postmortem brain RNA preparations. This is exemplified by comparison of Northern blots using amy37, which revealed apparent degradation products, to those of a GFAP probe, which consistently demonstrated intact glial mRNA.
  • the results indicate that limited Northern blot data are not amenable to generalized conclusions.
  • the observed results may reflect differences in mRNA-specific stability, differences in the susceptibility to degradation of neuronal versus glial RNA in neuropathoiogic states or as a result of postmortem processes, or a combination of these factors.
  • the sequence of the amy37 insert derived from the AD brain contains 1564 nucleotides which exactly match 75% of the coding region, and approximately 70% of the 3'-non-coding region of the corresponding fetal brain sequence (9).
  • the present results indicate that nearly one-half the AD precursor is identical to the fetal molecule including the region that is associated with senile plaque cores; this protein segment begins at amino acid 597 and extends for 42 or 43 amino acids (9).
  • CosA2 a monkey kidney cell line that has been successfully transformed by SV40 virus (44).
  • the CosA2 cell line is capable of producing low levels of the SV40 T antigen which is needed both for efficient early promotor function as well as replication.
  • the early SV40 promotor has been shown to function in a variety of systems, CosA2 is selected as an appropriate positive control.
  • Kidney cells appear to express the amyloid gene, as demonstrated by Northern blot criteria with a probe that included the A4 region (61).
  • HEP G2 is a human liver cell line which has been used to express Factor IX cDNA, the latter was cloned and characterized.
  • SKNSH Two neuroblastoma cell lines, SKNSH (35) and Lan I (57) are of confirmed neurogenic origin.
  • Rat pheochromacytoma PC12 cells are used since they express neuron-specific marker (neurofilament proteins) particularly in the presence of nerve growth factor (47, 41).
  • the A172 and HS683 cell lines are of confirmed glial origin (43, 52).
  • Bahmanyar et al. (33) and Kang et al. (9) it was said that amyloid mRNA was detected in certain glial ceils of brain.
  • the above-mentioned cell lines were selected on the basis of preliminary data associated with the ease of transfection with foreign DNA, ease of growth, and their susceptibility to the antibiotic genaticin; these are used as selective genetic markers.
  • the JC viral control element is used in some experiments to specifically establish AD amyloid cDNA expression in human brain cells.
  • the JC virus unlike SV40, has a very tight host, tissue, and cellular specificity (42). The virus seems to replicate in human brain. The host range specificity can be eliminated when direct DNA transfections or microinjections are done, but the tissue and cellular specific expression appears to be highly dependent on the enhancer elements and tissue-specific factors.
  • the decision to utilize co-transfection with selection for genaticin (G418) resistance was based upon the following considerations: (a) selection for a biochemical marker preselects for cells competent for the uptake of DNA (63); (b) the procedure removes from the population spontaneously transformed cells which have not incorporated DNA, for example, in some cells, like NIH 3T3 mouse fibrobiasts, the mere physical presence of calcium phosphate precipitated DNA can induce morphologically altered foci; (c) ceils which incorporate a selectable marker are likely to have incorporated an average of 3X10 3 kb from the coprecipitated DNA. A total of 10 3 G418 resistant colonies would likely have incorporated in total 3 ⁇ 10 6 kb of coprecipitated DNA which is about a genome equivalent.
  • the approach is to transfect various cell lines, e.g., neuronal, glial, kidney and liver with the amyloid cDNA using heterologous regulatory elements.
  • the appropriate gene expression control elements are needed. These are eukaryotic or prokaryotic, homologous or heterologous. Especially when one wishes to express eukaryotic cDNA copies of the eukaryotic genes in eukaryotic host systems, transcriptional and translational signals recognized by appropriate host elements are essential.
  • the homologous promotor and control elements for ⁇ -amyloid gene expression have not been isolated and characterized.
  • the hetero- logous control regions derived from the SV40 and JC viruses are used. The decision to choose SV40 regulatory elements vs.
  • viral control elements e.g., papilloma or retroviruses
  • SV40 control elements are the best studied;
  • they have been used to express a variety of cDNAs in a wide variety of ceil lines;
  • our research for over a decade, has involved a major portion of the original molecular biological studies of SV40 which involved characterizing and analyzing the viral genome and defining promoters, terminators, etc. (e.g. see: 50, 60 and 68).
  • the SV40 based vectors described below, were chosen to link with the amy37 cDNA insert.
  • the transfected cells are grown in a medium containing Geniticin.
  • the transfected cells expressing the brain amyloid, and resistant to Geniticin are cloned, characterized, propagated, and further developed into established cell lines according to Fasano, et al. (40).
  • the starting vector pKo + RIML is composed of PML 2 (a derivative of pBR322 lacking sequences poisonous for monkey kidney cell replication), the Lac UV5 promotor of E. coli and SV40 sequences covering the enhancer, origin of replication, early promotor, small "t" antigen splice sites and polyadenylation sites (Fig. 7).
  • Figure 8 compares DNA sequences flanking the unique cloning sites of the described vectors. The modification of the existing plasmid was done in such a way that the 3 variant plasmids contained one of the 3 segments of SV40 sequences all starting at the Bgl I site but terminating at different positions within the SV40 t/T coding region covering all 3 potential translating frames.
  • the schematic diagram for this construction is depicted in Figure 7.
  • the vectors are as follows: (a) Min 1, 2 and 3 vectors which read in the three frames starting from the SV40 T antigen; these can be used for inserting cDNA cut with Eco RI (the amyloid precursor cDNA has internal Eco RI sites as shown by Kang et al. , (9) and Zain et al., (65, 66). Of further importance is that the two Xba sites in the Min vectors separate the eukaryotic sequences from the prokaryotic regions.
  • the Xba sequence is not present as an internal restriction site in AD amyloid cDNA);
  • Mas 1, 2 and 3 vectors contain a unique Sac II site in lieu of the Eco RI cloning site for expressing the full length amyloid cDNA;
  • vectors with the JC virus control elements that may have preference for human brain cell transfections, referred to as Moh 1, 2, 3 and Ameer 1, 2, 3, are described subsequently.
  • the SV40 enhancer, promotor and DNA replication origin region are replaced with human JC virus control elements to produce the Moh and Ameer vectors (Fig. 7).
  • the JC virus causes Progressive Multifocal Leukoencephalopathy, a progressive demyelinating brain disease.
  • the JC virus has a structure very similar to SV40 virus, but has a very tight host and tissue specificity range (42). By transfeeting the cells with the derived DNA, the species barriers can be eliminated, but the tissuespecific expression is highly dependent on the enhancer elements (69). Therefore, the SV40 enhancers, promotor, DNA replication origin region of the Min 1, 2, 3 and Mas 1, 2 , 3 vectors are replaced to generate the new vectors i.e., the Moh and Ameer series. All vectors are characterized by restriction enzyme analysis, sequence analysis (Fig. 8) and transfection competency. The diagrammatic schemes for such vector constructions is shown in Figure 7.
  • Min, Mas, Moh and Ameer vectors are suitable for the transgenic mouse studies as well as the cellular transfection studies.
  • Xba I digestion of the recombinants separates bacterial sequences, harmful to eukaryotic gene expression, from the AD amyloid gene, especially for microinjection into mouse fertilized eggs.
  • DNA transfections are carried out using modifications of the basic technique of Graham S Van der Eb (46).
  • the cells are cotransfected with plasmids carrying the CAT (chloramphenicol acetyl transferase) gene and its expression product measured as a function of transfection.
  • CAT chloramphenicol acetyl transferase
  • Table I Typical CAT assays are shown in Table I.
  • various methods of transfection are used, e.g., using CaPO 4 or DEAE dextran to precipitate the transfecting DNA. The protocols are described below.
  • CosA2 HS683, A172 and HepG2 all gave satisfactory results using the CaPO 4 method.
  • CosA2 responded equally well to DEAE dextran precipitation. With SKNSH, some transfection was observed.
  • C 6 and PC12 two mouse cell lines, appear positive in initial transfection studies:
  • Transfection efficiency was checked using the CAT assay (Table I). Immunostaining of transfected cells using the mixture of A4 amyloid mabs (see copending application. Serial No. 105,751, filed 10/8/87, incorporated by reference herein in its entirety) is done to check for overproduction of ⁇ amyloid (A4) peptide. The results of immunostaining experiments are being confirmed by transfeeting larger number of cells, isolating the proteins synthesized and detecting the A4 peptide by Western blot analysis using the mab antibodies mentioned above.
  • in situ hybridizations are carried out on transfected cells and control mock transfected cells using high specific activity Amy37 insert riboprobes (55, 66). These data are further confirmed by Northern blot analysis of the mRNA using amyloid specific cDNA probes from Amy37 inserts (see Example 1).
  • cell extracts are prepared by suspending 10 6 cells in 100 ⁇ l of 0.25 M Tris, pH 8, freeze and thaw x 3, centrifuge and use the supernatant 10 ⁇ l of cell extract, 9.75 ⁇ l of 0.25 M Tris/HCl, pH 7.8, 4 ⁇ l of 14 C chloramphenicol (Amersham) (0.1 ⁇ l) and 1.25 ⁇ l 40 mM Acetyl COA are mixed, incubated at 37oC for an hour, and extracted with ethylacetate (0.3 ml).
  • the first step in this process is to titrate the optimal amount of genaticin needed to kill the cells. Since each cell type has a different degree of resistance towards genaticin, HS683, HepG 2 , CosA 2 , and SKNSH cells were titrated at 0-0.6 gm/litre of genaticin in the media and the level of survival of these cells was measured on each day following drug treatment. Both the glial (HS683) and neuronal (SKNSH) cells responded very well to the drug between 0.2-0.4 gm/litre concentration. These experiments were repeated for the human liver (HepG2), kidney (CosA2), C6 mouse glioma and PC12 mouse cells.
  • Immunologic and in situ hybridization protocols using antibody probes for the characterization of cells and transgenic mice are carried out by previously described methods (38, 49, 34).
  • the same vectors described for transfection studies, Min, Mas, Moh and Ameer are used and applied towards the preparation of transgenic mice.
  • the exact nature of these sequences is not known, except for a region from plasmid pBR322, which has been eliminated in the pko-vector series (the precursors of the Min, Mas, Moh and Ameer vectors) , which are poisonous for monkey kidney cells. Therefore, the vectors are designed in such a way that eukaryotic sequences can be easily separated (by digestion with Xba I enzyme) from the prokaryotic sequences.
  • the aim is to generate animals that express only subdomains of the amyloid precursor (A4 and non-A4 domains using Min and Moh vectors); or, in the total precursor cDNA harboring either SV40 control elements, or JC control elements (Mas and Ameer vectors). Expression may occur in neurons or glia.
  • SV40 control elements or JC control elements (Mas and Ameer vectors).
  • JC control elements Mas and Ameer vectors.
  • Expression may occur in neurons or glia.
  • initial studies make use of vectors derived from SV40, other studies use neuron-specific regulatory elements. These elements are the portions of the genome that contain the control region of neurofilament protein expression or the ⁇ -amyloid gene's natural control region isolated from AD genomic libraries.
  • the frequency of integration includes the form, of DNA (linear vs. supercoiled), its purity, concentration and the buffer in which the DNA is dissolved.
  • the DNA for microinjection should be free of all contaminants that might harm the egg; e.g., phenol, ethanol, enzymes and particulate matter (that may clog the injection needle). Therefore, the DNA is purified thoroughly by CsCl 2 density gradient centrifugation (see below), and prior to microinjection, all samples are filtered through 0.2 ⁇ m filters.
  • DNA insert containing only eukaryotic sequences
  • DNA insert is isolated by restriction endonuciease digestion followed by agarose gel electrophoresis, and purification by passage through a DEAE-sepharose column.
  • CsCl 2 purification is utilized.
  • 10 ⁇ g of the DNA insert is dissolved in 2.4 ml of 10 mM Tris, pH 7.9, 1 mM EDTA and exactly 3 gms of ultrapure CsCl is added. After dissolving the CsCl, the density of the solution is checked to make sure it is 1.70 ⁇ 0.01 gm/ml.
  • the solution is transferred to a clean 1.3 ⁇ 5 cm polyallomer ultracentrifuge tube, covered with light paraffin oil and centrifuged for 48 hours in a SW50.1 rotor at 20oC and 40,000 rpm. 0.2 ml fractions are carefully collected from the bottom of the tube, and the middle 8 tubes are assayed for DNA by running 2 ⁇ l on a miniagarose gel. Fractions containing the purified DNA are pooled and dialyzed against a large volume of injection buffer (10 mM Tris, pH 7.4, 0.2 mM EDTA) changing the buffer several times over a 48 h period. The DNA concentration is adjusted to 5 ⁇ g/ml, aliguoted into sterile Eppendorf tubes, lyophilized and stored at -20oC.
  • the healthy eggs are cultured in vitro for 3-5 days until they have reached the blastocyte stage, in M 2 media (36).
  • the recipient female mice, 6-8 weeks old and weighing 20 gm, are mated to vasectomized males at least 2.5 days before the transfer.
  • the animals are maintained in a constant light-dark cycle (7 p.m.-5 a.m. dark, 5 a.m.-7 p.m. light).
  • the fertilized eggs are dissected out several hours before they are to be injected.
  • a 4-6 week old superovulated female (B6XCBA F1) generally yields 20-30 eggs.
  • the abdominal cavity is opened, the oviduct and ovary is pulled out, and cut between the oviduct and ovary.
  • the oviduct and the attached segment of the uterus are transferred to a 35 mm petri dish containing M2 media at room temperature.
  • M2 medium containing 300 ⁇ g/ml of hyaluronidase is placed at room temperature. While viewing through a stereomicroscope, the eggs are pushed out gently by squeezing the oviduct with blunt forceps and allowed to incubate until the cumulus cells fall off.
  • the eggs are rinsed to get rid of the enzyme and transferred to a fresh dish of M2 within 1-2 minutes after the cumulus falls.
  • the eggs are transferred to M16 media for culture at 37oC and incubated to get 3.5 day blastocysts.
  • M16 is a modified Krebs-Ringer bicarbonate solution which is very similar to Whittens medium (62).
  • mice that develop from injected eggs are called "founder" mice.
  • transgenic matings are started to establish a transgenic line.
  • the male founder is placed with two females, which are checked each day and replaced with new females as soon as each is plugged. In this manner, the male can sire many litters within a few weeks.
  • a male has plugged 6-8 females, he is sacrificed, if necessary, for the analysis of gene expression.
  • female founders after she has given birth and raised at least several litters, she is sacrificed for analysis of gene expression. None of the animals are sacrificed until positive transgenic progeny are identified.
  • Alzheimer's Disease Molecular Genetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention se rapporte à des molécules d'ADNc et d'ADN recombinant encodant l'amyloïde A4, notamment l'amyloïde AD, provenant du cerveau humain d'un patient atteint de la maladie d'Alzheimer. L'invention concerne également des lignées cellulaires eucaryotes et des souris transgéniques qui sont transformées avec des vecteurs contenant de l'ADNc qui encode l'amyloïde A4.
PCT/US1989/000130 1988-01-13 1989-01-13 Constructions genetiques renfermant le gene amyloide cerebral d'alzheimer WO1989006689A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14342388A 1988-01-13 1988-01-13
US143,423 1988-01-13

Publications (1)

Publication Number Publication Date
WO1989006689A1 true WO1989006689A1 (fr) 1989-07-27

Family

ID=22504008

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1989/000130 WO1989006689A1 (fr) 1988-01-13 1989-01-13 Constructions genetiques renfermant le gene amyloide cerebral d'alzheimer

Country Status (2)

Country Link
AU (1) AU3056289A (fr)
WO (1) WO1989006689A1 (fr)

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991009120A1 (fr) * 1989-12-09 1991-06-27 Medical Research Council Modele d'animal in vivo pour l'etude de la maladie d'alzheimer
EP0451700A1 (fr) * 1990-04-10 1991-10-16 Miles Inc. Minigènes APP recombinants pour l'expression dans des souris transgéniques comme modèles de la maladie d'Alzheimer
WO1992006187A1 (fr) * 1990-09-28 1992-04-16 The Upjohn Company Animaux transgeniques porteurs d'un gene de precurseur amyloide d'alzheimer
WO1993002189A1 (fr) * 1991-07-18 1993-02-04 The Regents Of The University Of California Modeles animaux transgeniques pour l'etude de la maladie d'alzheimer
EP0647268A4 (fr) * 1990-06-15 1993-05-27 Scios Nova Inc Mammifere transgenique non humain presentant la pathologie de formation d'amyloides de la maladie d'alzheimer.
US5221607A (en) * 1989-09-18 1993-06-22 Scios Nova Inc. Assays and reagents for amyloid deposition
WO1993014200A1 (fr) * 1992-01-07 1993-07-22 Tsi Corporation Modeles d'animaux transgeniques utilises pour tester des traitements potentiels relatifs a la maladie d'alzheimer
EP0561087A1 (fr) * 1992-03-20 1993-09-22 N.V. Innogenetics S.A. Forme mutée du gène de la protéine du précurseur beta-amyloide
WO1994021683A1 (fr) * 1992-03-20 1994-09-29 N.V. Innogenetics S.A. FORME MUTANTE DU GENE DE PROTEINE PRECURSEUR DE β-AMYLOIDE
US5604131A (en) * 1992-01-07 1997-02-18 Athena Neurosciences, Inc. cDNA-genomic DNA hybrid sequence encoding APP770 containing a genomic DNA insert of the KI and OX-2 regions
US5849999A (en) * 1996-10-16 1998-12-15 The Mclean Hospital Corporation Transgenic non-human mice expressing Flag-APP-C100 protein develop alzheimer's disease brain morphology and behavior
US5877399A (en) * 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
US5912410A (en) * 1990-06-15 1999-06-15 Scios Inc. Transgenic non-human mice displaying the amyloid-forming pathology of alzheimer's disease
US6037521A (en) * 1993-11-12 2000-03-14 Hoechst Japan Limited Transgenic mouse expressing an β-Amyloid transgene
US6262335B1 (en) 1994-01-27 2001-07-17 Johns Hopkins University Transgenic mice expressing APP mutant at amino acids 717, 721 and 722
EP0971033A3 (fr) * 1991-01-21 2003-11-12 Elan Pharmaceuticals, Inc. Essai et modèle pour la maladie d'Alzheimer
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US6717031B2 (en) 1995-06-07 2004-04-06 Kate Dora Games Method for selecting a transgenic mouse model of alzheimer's disease
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6787140B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
US6808712B2 (en) 1997-12-02 2004-10-26 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6875434B1 (en) 1997-12-02 2005-04-05 Neuralab Limited Methods of treatment of Alzheimer's disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US7432414B2 (en) 2003-05-30 2008-10-07 Merck & Co., Inc. Transgenic mouse having an amyloid precursor protein with a modified beta secretase cleavage site
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7871615B2 (en) 2003-05-30 2011-01-18 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7893214B2 (en) 1997-12-02 2011-02-22 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7977316B2 (en) 1999-06-01 2011-07-12 Elan Pharmaceuticals, Inc. Prevention and treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US8105594B2 (en) 1998-05-21 2012-01-31 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US8128928B2 (en) 2002-03-12 2012-03-06 Wyeth Llc Humanized antibodies that recognize beta amyloid peptide
US8613920B2 (en) 2007-07-27 2013-12-24 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8916165B2 (en) 2004-12-15 2014-12-23 Janssen Alzheimer Immunotherapy Humanized Aβ antibodies for use in improving cognition
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US9644025B2 (en) 2007-10-17 2017-05-09 Wyeth Llc Immunotherapy regimes dependent on ApoE status
US10208109B2 (en) 2005-11-30 2019-02-19 Abbvie Inc. Monoclonal antibodies against amyloid beta protein and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4579821A (en) * 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
US4666829A (en) * 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
US4728605A (en) * 1984-07-31 1988-03-01 Fudenberg Herman H Methods for recognizing and diagnosing subsets of Alzheimer's disease associated with immune system dysfunction, and for the in vitro testing of possible therapeutic agents for treatment of same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4579821A (en) * 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
US4728605A (en) * 1984-07-31 1988-03-01 Fudenberg Herman H Methods for recognizing and diagnosing subsets of Alzheimer's disease associated with immune system dysfunction, and for the in vitro testing of possible therapeutic agents for treatment of same
US4666829A (en) * 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EMBO JOURNAL 6(12) 1987, GOEDERT, "Neuronal Localization of Amyloid Beta Protein Precursor in RNA in Normal Human Brain and in Alzheimer Disease", pages 3627-3632. *
NATURE 325, 19 February 1987, KANG et al., "The Precursor of Alzheimer's Disease Amyloids A4 Protein Resembles a Cell Surface Receptor", pages 733-736. *

Cited By (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5221607A (en) * 1989-09-18 1993-06-22 Scios Nova Inc. Assays and reagents for amyloid deposition
WO1991009120A1 (fr) * 1989-12-09 1991-06-27 Medical Research Council Modele d'animal in vivo pour l'etude de la maladie d'alzheimer
EP0451700A1 (fr) * 1990-04-10 1991-10-16 Miles Inc. Minigènes APP recombinants pour l'expression dans des souris transgéniques comme modèles de la maladie d'Alzheimer
US5912410A (en) * 1990-06-15 1999-06-15 Scios Inc. Transgenic non-human mice displaying the amyloid-forming pathology of alzheimer's disease
EP0647268A4 (fr) * 1990-06-15 1993-05-27 Scios Nova Inc Mammifere transgenique non humain presentant la pathologie de formation d'amyloides de la maladie d'alzheimer.
US5387742A (en) * 1990-06-15 1995-02-07 Scios Nova Inc. Transgenic mice displaying the amyloid-forming pathology of alzheimer's disease
EP0647268A1 (fr) * 1990-06-15 1995-04-12 Scios Nova Inc. Mammifere transgenique non humain presentant la pathologie de formation d'amyloides de la maladie d'alzheimer
WO1992006187A1 (fr) * 1990-09-28 1992-04-16 The Upjohn Company Animaux transgeniques porteurs d'un gene de precurseur amyloide d'alzheimer
EP0971033A3 (fr) * 1991-01-21 2003-11-12 Elan Pharmaceuticals, Inc. Essai et modèle pour la maladie d'Alzheimer
US5672805A (en) * 1991-07-18 1997-09-30 The Regents Of The University Of California Transgenic mice expressing the neurotoxic C-terminus of β-amyloid precursor protein
WO1993002189A1 (fr) * 1991-07-18 1993-02-04 The Regents Of The University Of California Modeles animaux transgeniques pour l'etude de la maladie d'alzheimer
US5604131A (en) * 1992-01-07 1997-02-18 Athena Neurosciences, Inc. cDNA-genomic DNA hybrid sequence encoding APP770 containing a genomic DNA insert of the KI and OX-2 regions
US5720936A (en) * 1992-01-07 1998-02-24 Athena Neurosciences, Inc. Transgenic mouse assay for compounds affecting amyloid protein processing
US5811633A (en) * 1992-01-07 1998-09-22 Wadsworth; Samuel Transgenic mouse expressing APP770
WO1993014200A1 (fr) * 1992-01-07 1993-07-22 Tsi Corporation Modeles d'animaux transgeniques utilises pour tester des traitements potentiels relatifs a la maladie d'alzheimer
EP0561087A1 (fr) * 1992-03-20 1993-09-22 N.V. Innogenetics S.A. Forme mutée du gène de la protéine du précurseur beta-amyloide
WO1994021683A1 (fr) * 1992-03-20 1994-09-29 N.V. Innogenetics S.A. FORME MUTANTE DU GENE DE PROTEINE PRECURSEUR DE β-AMYLOIDE
US5525714A (en) * 1992-03-20 1996-06-11 N. V. Innogenetics S.A. Mutated form of the β-amyloid precursor protein gene
US6037521A (en) * 1993-11-12 2000-03-14 Hoechst Japan Limited Transgenic mouse expressing an β-Amyloid transgene
US6262335B1 (en) 1994-01-27 2001-07-17 Johns Hopkins University Transgenic mice expressing APP mutant at amino acids 717, 721 and 722
US5877399A (en) * 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
US6509515B2 (en) 1994-01-27 2003-01-21 Regents Of The University Of Minnesota Transgenic mice expressing mutant human APP and forming congo red staining plaques
US6717031B2 (en) 1995-06-07 2004-04-06 Kate Dora Games Method for selecting a transgenic mouse model of alzheimer's disease
US5849999A (en) * 1996-10-16 1998-12-15 The Mclean Hospital Corporation Transgenic non-human mice expressing Flag-APP-C100 protein develop alzheimer's disease brain morphology and behavior
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US6818218B2 (en) 1997-12-02 2004-11-16 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6787140B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6787144B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6787139B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6787138B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US8034339B2 (en) 1997-12-02 2011-10-11 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidogenic disease
US6787143B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6808712B2 (en) 1997-12-02 2004-10-26 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6875434B1 (en) 1997-12-02 2005-04-05 Neuralab Limited Methods of treatment of Alzheimer's disease
US6890535B1 (en) 1997-12-02 2005-05-10 Neuralab Limited Pharmaceutical compositions and methods for treatment of amyloid diseases
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US6936246B1 (en) 1997-12-02 2005-08-30 Neuralab Limited Passive immunization of ASCR for prion disorders
US6982084B2 (en) 1997-12-02 2006-01-03 Neuralab Limited Prevention and treatment of amyloidogenic disease
US9051363B2 (en) 1997-12-02 2015-06-09 Janssen Sciences Ireland Uc Humanized antibodies that recognize beta amyloid peptide
US8642044B2 (en) 1997-12-02 2014-02-04 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidogenic disease
US8034348B2 (en) 1997-12-02 2011-10-11 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidogenic disease
US8535673B2 (en) 1997-12-02 2013-09-17 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidogenic disease
US7893214B2 (en) 1997-12-02 2011-02-22 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US8105594B2 (en) 1998-05-21 2012-01-31 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
US8124081B2 (en) 1999-06-01 2012-02-28 Crimagua Limited Prevention and treatment of amyloidogenic diseases
US7977316B2 (en) 1999-06-01 2011-07-12 Elan Pharmaceuticals, Inc. Prevention and treatment of amyloidogenic diseases
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US8128928B2 (en) 2002-03-12 2012-03-06 Wyeth Llc Humanized antibodies that recognize beta amyloid peptide
US10464976B2 (en) 2003-01-31 2019-11-05 AbbVie Deutschland GmbH & Co. KG Amyloid β(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US7871615B2 (en) 2003-05-30 2011-01-18 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7432414B2 (en) 2003-05-30 2008-10-07 Merck & Co., Inc. Transgenic mouse having an amyloid precursor protein with a modified beta secretase cleavage site
US8916165B2 (en) 2004-12-15 2014-12-23 Janssen Alzheimer Immunotherapy Humanized Aβ antibodies for use in improving cognition
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies
US10538581B2 (en) 2005-11-30 2020-01-21 Abbvie Inc. Anti-Aβ globulomer 4D10 antibodies
US10323084B2 (en) 2005-11-30 2019-06-18 Abbvie Inc. Monoclonal antibodies against amyloid beta protein and uses thereof
US10208109B2 (en) 2005-11-30 2019-02-19 Abbvie Inc. Monoclonal antibodies against amyloid beta protein and uses thereof
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US9951125B2 (en) 2006-11-30 2018-04-24 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9359430B2 (en) 2006-11-30 2016-06-07 Abbvie Inc. Abeta conformer selective anti-Abeta globulomer monoclonal antibodies
US9394360B2 (en) 2006-11-30 2016-07-19 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US8613920B2 (en) 2007-07-27 2013-12-24 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US9644025B2 (en) 2007-10-17 2017-05-09 Wyeth Llc Immunotherapy regimes dependent on ApoE status
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US9822171B2 (en) 2010-04-15 2017-11-21 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US10047121B2 (en) 2010-08-14 2018-08-14 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins

Also Published As

Publication number Publication date
AU3056289A (en) 1989-08-11

Similar Documents

Publication Publication Date Title
US5547841A (en) In vitro method for screening for drugs that inhibit production or degradation of human A4-amyloid
WO1989006689A1 (fr) Constructions genetiques renfermant le gene amyloide cerebral d'alzheimer
US5387742A (en) Transgenic mice displaying the amyloid-forming pathology of alzheimer's disease
US5912410A (en) Transgenic non-human mice displaying the amyloid-forming pathology of alzheimer's disease
CA2174429C (fr) Animaux transgeniques hebergeant un gene allele app presentant une mutation suedoise
US6037521A (en) Transgenic mouse expressing an β-Amyloid transgene
CA2101774C (fr) Test et modele pour la maladie d'alzheimer
EP0451700A1 (fr) Minigènes APP recombinants pour l'expression dans des souris transgéniques comme modèles de la maladie d'Alzheimer
JPH10504964A (ja) 家族性型ヒトアミロイド前駆タンパク質を発現するトランスジェニック動物
WO1994023049A2 (fr) Introduction et expression de grandes sequences genomiques chez des animaux transgeniques
WO1994023049A9 (fr) Introduction et expression de grandes sequences genomiques chez des animaux transgeniques
JP2010175548A (ja) Ｓｗｅｄｉｓｈ変異を有するＡＰＰ対立遺伝子を含有するトランスジェニック動物
CA2108548A1 (fr) Forme mutee du gene du precurseur de la proteine .beta.-amyloide
US5525714A (en) Mutated form of the β-amyloid precursor protein gene
US5777194A (en) Gene-targeted mice with humanized Aβ sequence and Swedish FAD mutation
WO1996034097A1 (fr) MAMMIFERES NON HUMAINS CIBLES PAR GENE PRESENTANT UN DEFICIT EN GENE SOD-1, EXPRIMANT UNE SEQUENCE Aβ HUMANISEE A MUTATION SUEDOISE DE FAD
WO1989006693A1 (fr) Sequences genetiques codant pour l'amyloide cerebrale d'alzheimer
Loring et al. Rational design of an animal model for Alzheimer's disease: introduction of multiple human genomic transgenes to reproduce AD pathology in a rodent
WO1994012627A1 (fr) Modeles d'animaux transgeniques utilises dans le traitement de la maladie d'alzheimer
AU782281B2 (en) Transgenic animals as models for neurodegenerative disease
JP2003517812A (ja) ＰｒＰ様遺伝子
US6958433B2 (en) Transgenic mice overexpressing aspartyl protease 2 (ASP2)
ZA200110477B (en) Transgenic animals as models for neurodegenerative disease.
GB2380196A (en) Transgenic animals with mutant human amyloid precursor protein sequences
Von Koch Molecular analysis of a homologue of the mouse beta-amyloid precursor protein, APLP2: Isolation of APLP2cDNA, characterization of the APLP2 gene promoter and gene targeting of APLP2

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR CH DE DK FI GB HU JP KP KR LK LU MC MG MW NL NO RO SD SE SU

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BJ CF CG CH CM DE FR GA GB IT LU ML MR NL SE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642